Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 7Neoplasms 3Skin Neoplasms 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Neoplasm Metastasis 1Fever 1Differentiated Thyroid Cancer (DTC) 1Ameloblastoma 1

Interventions

liposomal amphotericin B 2Vancomycin 2Cefepime 2trametinib 1pegfilgrastim 1dabrafenib 1ceftobiprole medocaril 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Levofloxacin 1Granulocyte-Macrophage Colony-Stimulating Factor 1Filgrastim 1Ciprofloxacin 1Caspofungin 1Bevacizumab 1Anti-Bacterial Agents 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Fever × dabrafenib × Clear all
NCT03551626 2025-04-29

COMBI-APlus

Novartis

Phase 3 Completed
552 enrolled 12 charts
Dermatologic

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡